-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
GP (33-41)
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/161928-86-5.gif)
| Category | Arenavirus |
| CAS | 161928-86-5 |
| Description | GP(33-41), a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus. |
Product Information
| Synonyms | H-Lys-Ala-Val-Tyr-Asn-Phe-Ala-Thr-Cys-OH; L-lysyl-L-alanyl-L-valyl-L-tyrosyl-L-asparaginyl-L-phenylalanyl-L-alanyl-L-threonyl-L-cysteine |
| IUPAC Name | (2R)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]-3-sulfanylpropanoic acid |
| Molecular Weight | 1016.18 |
| Molecular Formula | C46H69N11O13S |
| Canonical SMILES | CC(C)C(C(=O)NC(CC1=CC=C(C=C1)O)C(=O)NC(CC(=O)N)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(C)C(=O)NC(C(C)O)C(=O)NC(CS)C(=O)O)NC(=O)C(C)NC(=O)C(CCCCN)N |
| InChI | InChI=1S/C46H69N11O13S/c1-23(2)36(56-38(61)24(3)50-40(63)30(48)13-9-10-18-47)44(67)54-32(20-28-14-16-29(59)17-15-28)42(65)53-33(21-35(49)60)43(66)52-31(19-27-11-7-6-8-12-27)41(64)51-25(4)39(62)57-37(26(5)58)45(68)55-34(22-71)46(69)70/h6-8,11-12,14-17,23-26,30-34,36-37,58-59,71H,9-10,13,18-22,47-48H2,1-5H3,(H2,49,60)(H,50,63)(H,51,64)(H,52,66)(H,53,65)(H,54,67)(H,55,68)(H,56,61)(H,57,62)(H,69,70)/t24-,25-,26+,30-,31-,32-,33-,34-,36-,37-/m0/s1 |
| InChIKey | OTXDHMGAEPLIQZ-ZVGUPDCISA-N |
| Boiling Point | 1490.5±65.0°C at 760 mmHg |
| Purity | ≥95% |
| Density | 1.3±0.1 g/cm3 |
| Solubility | Soluble in DMSO, Water |
| Appearance | White Lyophilized Powder |
| Storage | Store at -20°C |
| In Vitro | GP(33-41) sensitizes MC57 and T2-Db cells to lysis with ED50s of 0.9±0.6 and 2.5±0.7 nM The interaction between T cell receptors (TCR) and peptide-major histocompatibility complex (pMHC) antigens can lead to varying degrees of agonism (T cell activation), or antagonism. The P14 TCR recognises the lymphocytic choriomeningitis virus (LCMV)-derived peptide, GP(33-41) (KAVYNFATC), presents in the context of H-2D. |
| PSA | 20.23000 |
| Target | Arenavirus |
